In response to recent concerns about offers for certain Propofol 1% injection products that appear to be outside of the established distribution pathway, FDA's Drug Shortages Team would like to share the following information, which may be of interest to your members:
Propofol 1% Injection has been in short supply for approximately 2 months due to manufacturing issues. In response to the drug shortage, APP Pharmaceuticals is shipping Fresenius Propoven(r) 1% (propofol 1%) Injection directly to hospitals/surgery centers from their Chicago, IL location. Purchase of Propoven(r) through any other source (also known as "gray market distributors") is not recommended because the quality of the Propoven(r) from another source cannot be assured. Any offer to sell Propoven(r) by an entity other than APP Pharmaceuticals should be reported to drugshortages@fda.hhs.gov.
For additional information:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment